Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

by Momtaz, Parisa, Postow, Michael A
Published in Pharmgenomics Pers Med (2014)

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

by Kyi, Chrisann, Postow, Michael A
Published in Immunotherapy (2016)

Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications

by Postow, Michael A, Robson, Mark E
Published 2012

Combinations of Radiotherapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes

by Barker, Christopher A., Postow, Michael A.
Published in Int J Radiat Oncol Biol Phys (2014)

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

by Friedman, Claire F., Postow, Michael A.
Published in Curr Oncol Rep (2016)

Recent advances in understanding antitumor immunity

by Munhoz, Rodrigo Ramella, Postow, Michael Andrew
Published in F1000Res (2016)

Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone

by Rosner, Samuel, Sen, Filiz, Postow, Michael
Published in J Immunother Cancer (2017)

A step forward for patients with NRAS-mutant melanoma

by Postow, Michael A., Chapman, Paul B.
Published in Lancet Oncol (2017)

Clinical development of PD-1/PD-L1 in Advanced Melanoma

by Munhoz, Rodrigo Ramella, Postow, Michael Andrew
Published in Cancer J (2018)

Beyond Cancer Vaccines: A Reason for Future Optimism with Immunomodulatory Therapy

by Postow, Michael, Callahan, Margaret K., Wolchok, Jedd D.
Published 2011

Targeting Immune Checkpoints: Releasing the Restraints on Anti-tumor Immunity for Patients with Melanoma

by Postow, Michael A., Harding, James, Wolchok, Jedd D.
Published 2012

Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-Oncology Research

by Kidwell, Kelley M, Postow, Michael A., Panageas, Katherine S.
Published in Clin Cancer Res (2017)

Immunomodulatory Therapy for Melanoma: Ipilimumab and Beyond

by Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Published 2013

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

by Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Published in Front Oncol (2015)

Immune Checkpoint Blockade in Cancer Therapy

by Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D.
Published in J Clin Oncol (2015)

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

by Weber, Jeffrey S., Postow, Michael, Lao, Christopher D., Schadendorf, Dirk
Published in Oncologist (2016)

Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy In Need of Further Investigation

by Escorcia, Freddy E., Postow, Michael A., Barker, Christopher A.
Published in Cancer J (2017)

Ipilimumab in patients with melanoma and autoimmune disease

by Kyi, Chrisann, Carvajal, Richard D, Wolchok, Jedd D, Postow, Michael A
Published 2014

Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions

by Page, David B., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D.
Published 2013

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

by Ryder, Mabel, Callahan, Margaret, Postow, Michael A, Wolchok, Jedd, Fagin, James A
Published in Endocr Relat Cancer (2014)